Skip to main content

Epigenomics and Biopsytec Cross-License Genetic Technologies

SAN FRANCISCO, April 25 - German biotechs Epigenomics and Biopsytec said on Thursday that they have cross-licensed each other's genetic analysis technologies.


Epigenomics has exclusive rights to use Biopsytec's Identification of Linkage Disequilibrium technology in pharmaceutical research and diagnostics. Biopsytec has exclusive rights to use Epigenomics' DNA-methylation technologies in agricultural research.


Financial terms of the agreement were not disclosed.


Epigenomics said it would apply ILD technology to discovery of new drug targets and the identification of the genetic causes of adverse side-effects in patient populations involved in clinical trials.


Biopsytec, an agricultural genetics company, plans to use the DNA-methylation technology to turn on and off genes to improve the results of animal and plant breeding.


"With Biopsytec being an agricultural specialist and Epigenomics focusing exclusively on human health care, this agreement is a perfect fit," Arno Heuermann, CEO of Biopsytec, said in a statement. "Each company provides the other with the complementary technologies that enable a comprehensive and unique approach to the two very different markets."


Both companies are based in Berlin.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.